Hypomagnesaemia in kidney transplantation

Transplantation Reviews

Volumn 29, Issue 3, 2015, Pages 154-160

  Van Laecke, Steven ^a   Van Biesen, Wim ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; MAGNESIUM; TRANSIENT RECEPTOR POTENTIAL CHANNEL M6; CALCINEURIN INHIBITOR;

ARTERIAL STIFFNESS; BONE METABOLISM; CARDIOVASCULAR DISEASE; DELAYED GRAFT FUNCTION; DISEASE ASSOCIATION; DOWN REGULATION; GLUCOSE METABOLISM; HIGH RISK PATIENT; HUMAN; HYPOMAGNESEMIA; KIDNEY TRANSPLANTATION; MAGNESIUM BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; ADVERSE EFFECTS; BLOOD; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; MAGNESIUM DEFICIENCY; MALE; METABOLISM; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATIONS; PROCEDURES; RENAL TUBULAR TRANSPORT, INBORN ERRORS;

CALCINEURIN INHIBITORS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; MAGNESIUM; MAGNESIUM DEFICIENCY; MALE; POSTOPERATIVE COMPLICATIONS; RENAL TUBULAR TRANSPORT, INBORN ERRORS; RISK ASSESSMENT;

EID: 84952871676     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2015.05.002     Document Type: Review

References (113)

1. Lutsey P.L., Alonso A., Michos E.D., et al. Serum magnesium, phosphorus, and calcium are associated with risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Clin Nutr 2014, 100:756-764.
2. Akarolo-Anthony S.N., Jiménez M.C., Chiuve S.E., Spiegelman D., Willett W.C., Rexrode K.M. Plasma magnesium and risk of ischemic stroke among women. Stroke 2014, 45:2881-2886.
3. Guasch-Ferré M., Bulló M., Estruch R., et al. Dietary magnesium intake is inversely associated with mortality in adults at high cardiovascular disease risk. J Nutr 2014, 144:55-60.
4. Joosten M.M., Gansevoort R.T., Mukamal K.J., et al. Urinary and plasma magnesium and risk of ischemic heart disease. Am J Clin Nutr 2013, 97:1299-1306.
5. Peters K.E., Chubb S.A.P., Davis W.A., Davis T.M. The relationship between hypomagnesemia, metformin therapy and cardiovascular disease complicating type 2 diabetes: the Fremantle Diabetes Study. PLoS ONE 2013, 8:e74355.
6. Khan A.M., Lubitz S.A., Sullivan L.M., et al. Low serum magnesium and the development of atrial fibrillation in the community: the Framingham Heart Study. Circulation 2013, 127:33-38.
7. Al-Delaimy W.K., Rimm E.B., Willett W.C., Stampfer M.J., Hu F.B. Magnesium intake and risk of coronary heart disease among men. J Am Coll Nutr 2004, 23:63-70.
8. Reffelmann T., Dorr M., Ittermann T., et al. Low serum magnesium concentrations predict increase in left ventricular mass over 5years independently of common cardiovascular risk factors. Atherosclerosis 2010, 213:563-569.
9. Peacock J.M., Ohira T., Post W., Sotoodehnia N., Rosamond W., Folsom A.R. Serum magnesium and risk of sudden cardiac death in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2010, 160:464-470.
10. Van Laecke S., Nagler E.V., Verbeke F., Van Biesen W., Vanholder R. Hypomagnesemia and the risk of death and GFR decline in chronic kidney disease. Am J Med 2013, 126:825-831.
11. Sakaguchi Y., Fujii N., Shoji T., Hayashi T., Rakugi H., Isaka Y. Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int 2014, 85:174-181.
12. Del Gobbo L.C., Imamura F., Wu J.H., de Oliveira Otto M.C., Chiuve S.E., Mozaffarian D. Circulating and dietary magnesium and risk of cardiovascular disease: a systematic review and meta-analysis of prospective studies. Am J Clin Nutr 2013, 98:160-173.
13. Larsson S.C., Orsini N., Wolk A. Dietary magnesium intake and risk of stroke: a meta-analysis of prospective studies. Am J Clin Nutr 2012, 95:362-366.
14. Qu X., Jin F., Hao Y., et al. Magnesium and the risk of cardiovascular events: a meta-analysis of prospective cohort studies. PLoS ONE 2013, 8:e57720.
15. Khan A.M., Sullivan L., McCabe E., Levy D., Vasan R.S., Wang T.J. Lack of association between serum magnesium and the risks of hypertension and cardiovascular disease. Am Heart J 2010, 160:715-720.
16. Vaduganathan M., Greene S.J., Ambrosy A.P., et al. Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST trial). Am J Cardiol 2013, 112:1763-1769.
17. Levitan E.B., Shikany J.M., Ahmed A., et al. Calcium, magnesium and potassium intake and mortality in women with heart failure: the Women's Health Initiative. Br J Nutr 2013, 110:179-185.
18. Kass L., Weekes J., Carpenter L. Effect of magnesium supplementation on blood pressure: a meta-analysis. Eur J Clin Nutr 2012, 66:411-418.
19. Song Y., He K., Levitan E.B., Manson J.E., Liu S. Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes: a meta-analysis of randomized double-blind controlled trials. Diabet Med 2006, 23:1050-1056.
20. Hadjistavri L.S., Sarafidis P.A., Georgianos P.I., et al. Beneficial effects of oral magnesium supplementation on insulin sensitivity and serum lipid profile. Med Sci Monit 2010, 16:CR307-CR312.
21. Van Laecke S., Van Biesen W., Vanholder R. Hypomagnesaemia, the kidney and the vessels. Nephrol Dial Transplant 2012, 27:4003-4010.
22. Barbagallo M., Dominguez L.J., Galioto A., Pineo A., Belvedere M. Oral magnesium supplementation improves vascular function in elderly diabetic patients. Magnes Res 2010, 23:131-137.
23. Rosanoff A., Weaver C.M., Rude R.K. Suboptimal magnesium status in the United States: are the health consequences underestimated?. Nutr Rev 2012, 70:153-164.
24. Barbagallo M., Dominguez L.J. Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome and insulin resistance. Arch Biochem Biophys 2007, 458:40-47.
25. Barton C.H., Vaziri N.D., Martin D.C., Choi S., Alikhani S. Hypomagnesemia and renal magnesium wasting in renal transplant recipients receiving cyclosporine. Am J Med 1987, 83:693-699.
26. Navaneethan S.D., Sankarasubbaiyan S., Gross M.D., Jeevanantham V., Monk R.D. Tacrolimus-associated hypomagnesemia in renal transplant recipients. Transplant Proc 2006, 38:1320-1322.
27. Higgins R.M., Hart P., Lam F.T., Kashi H. Conversion from tacrolimus to cyclosporine in stable renal transplant patients: safety, metabolic changes, and pharmacokinetic comparison. Transplantation 2000, 69:1736-1739.
28. Mazzola B.L., Vannini S.D.P., Truttmann A.C., et al. Long-term calcineurin inhibition and magnesium balance after renal transplantation. Transpl Int 2003, 16:76-81.
29. Ledeganck K.J., De Winter B.Y., Van den Driessche A., et al. Magnesium loss in cyclosporine-treated patients is related to renal epidermal growth factor downregulation. Nephrol Dial Transplant 2014, 29:1097-1102.
30. Nijenhuis T., Hoenderop J.G.J., Bindels R.J.M. Downregulation of Ca2+ and Mg2+ Transport Proteins in the Kidney Explains Tacrolimus (FK506)-Induced Hypercalciuria and Hypomagnesemia. J Am Soc Nephrol 2004, 15:549-557.
31. Van Ende C., Van Laecke S., Marechal C., et al. Proton-pump inhibitors do not influence serum magnesium levels in renal transplant recipients. J Nephrol 2014, [ahead of publication].
32. Lee C.-T., Ng H.-Y., Lien Y.-H., et al. Effects of cyclosporine, tacrolimus and rapamycin on renal calcium transport and vitamin D metabolism. Am J Nephrol 2011, 34:87-94.
33. da Silva C.A., de Braganca A.C., Shimizu M.H.M., et al. Rosiglitazone prevents sirolimus-induced hypomagnesemia, hypokalemia, and downregulation of NKCC2 protein expression. Am J Physiol Renal Physiol 2009, 297:F916-F922.
34. Ikari A., Sanada A., Sawada H., Okude C., Tonegawa C., Sugatani J. Decrease in transient receptor potential melastatin 6 mRNA stability caused by rapamycin in renal tubular epithelial cells. Biochim Biophys Acta Biomembr 2011, 1808:1502-1508.
35. Charpentier B., Groth C.G., Bäckman L., et al. Bicêtre hospital experience with sirolimus-based therapy in human renal transplantation: the sirolimus European renal transplant study. Transplant Proc 2003, 35:S58-S61.
36. Morales J.M., Wramner L., Kreis H., et al. Sirolimus does Not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002, 2:436-442.
37. Andoh T.F., Burdmann E.A., Fransechini N., Houghton D.C., Bennett W.M. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int 1996, 50:1110-1117.
38. Allegra A., Corica F., Ientile R., et al. Plasma (total and ionized), erythrocyte and platelet magnesium levels in renal transplant recipients during cyclosporine and/or azathioprine treatment. Magnes Res 1998, 11:11-18.
39. Frost L., Danielsen H., Dorup I., Kjaer T., Pedersen E.B. Skeletal muscle magnesium content during cyclosporin and azathioprine treatment in renal transplant recipients. Nephrol Dial Transplant 1993, 8:79-83.
40. Ekberg H., Tedesco-Silva H., Demirbas A., et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007, 357:2562-2575.
41. Holdaas H., Fellström B., Jardine A.G., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003, 361:2024-2031.
42. Vincenti F., Friman S., Scheuermann E., et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007, 7:1506-1514.
43. Budde K., Becker T., Arns W., et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011, 377:837-847.
44. Vincenti F., Larsen C.P., Alberu J., et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012, 12:210-217.
45. Vannini S.D., Mazzola B.L., Rodoni L., et al. Permanently reduced plasma ionized magnesium among renal transplant recipients on cyclosporine. Transpl Int 1999, 12:244-249.
46. Stevens R.B., Lane J.T., Boerner B.P., et al. Single-dose rATG induction at renal transplantation: superior renal function and glucoregulation with less hypomagnesemia. Clin Transplant 2012, 26:123-132.
47. Van Laecke S., Desideri F., Geerts A., et al. Hypomagnesemia and the risk of new-onset diabetes after liver transplantation. Liver Transpl 2010, 16:1278-1287.
48. Van de Cauter J., Sennesael J., Haentjens P. Long-term evolution of the mineral metabolism after renal transplantation: a prospective, single-center cohort study. Transplant Proc 2011, 43:3470-3475.
49. Millane T.A., Jennison S.H., Mann J.M., Holt D.W., McKenna W.J., Camm A.J. Myocardial magnesium depletion associated with prolonged hypomagnesemia: a longitudinal study in heart transplant recipients. J Am Coll Cardiol 1992, 20:806-812.
50. Millane T., Wilson A.J., Patel M.K., et al. Mitochondrial calcium deposition in association with cyclosporine therapy and myocardial magnesium depletion: a serial histologic study in heart transplant recipients. J Heart Lung Transplant 1994, 13:473-480.
51. Elgend H.M., El Moghazy W.M., Uemoto S., Fukuda K. Pre transplant serum magnesium level predicts outcome after pediatric living donor liver transplantation. Ann Transplant 2012, 17:29-37.
52. Stoumpos S., Jardine A.G., Mark P.B. Cardiovascular morbidity and mortality after kidney transplantation. Transpl Int 2014, 28:10-21.
53. Holzmacher R., Kendziorski C., Hofman R.M., Jaffery J., Becker B., Djamali A. Low serum magnesium is associated with decreased graft survival in patients with chronic cyclosporin nephrotoxicity. Nephrol Dial Transplant 2005, 20:1456-1462.
54. Tin A., Grams M.E., Maruthur N.M., et al. Results from the Atherosclerosis Risk in Communities study suggest that low serum magnesium is associated with incident kidney disease. Kidney Int 2015, 87:820-827.
55. Rob P.M., Lebeau A., Nobiling R., et al. Magnesium metabolism: Basic aspects and implications of ciclosporine toxicity in rats. Nephron 1996, 72:59-66.
56. Asai T., Nakatani T., Yamanaka S., et al. Magnesium supplementation prevents experimental chronic cyclosporine a nephrotoxicity via renin-angiotensin system independent mechanism. Transplantation 2002, 74:784-791.
57. Miura K., Nakatani T., Asai T., et al. Role of hypomagnesemia in chronic cyclosporine nephropathy. Transplantation 2002, 73:340-347.
58. Carlos C.P., Mendes G.E.F., Miquelin A.R., et al. Macrophage depletion attenuates chronic cyclosporine a nephrotoxicity. Transplantation 2010, 89:1362-1370.
59. Yuan J., Zhou J., Chen B.C., et al. Magnesium supplementation prevents chronic cyclosporine nephrotoxicity via adjusting nitric oxide synthase activity. Transplant Proc 2005, 37:1892-1895.
60. Asai T., Nakatani T., Tamada S., et al. Activation of transcription factors AP-1 and NF-[kappa]B in chronic cyclosporine A nephrotoxicity: role in beneficial effects of magnesium supplementation1. Transplantation 2003, 75:1040-1044.
61. Tsoulfas G., Geller D.A. NF-κB in transplantation: friend or foe?. Transpl Infect Dis 2001, 3:212-219.
62. Mervaala E.M.A., Pere A.-K., Lindgren L., et al. Effects of dietary sodium and magnesium on cyclosporin A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats. Hypertension 1997, 29:822-827.
63. Pere A.-K., Lindgren L., Tuomainen P., et al. Dietary potassium and magnesium supplementation in cyclosporine-induced hypertension and nephrotoxicity. Kidney Int 2000, 58:2462-2472.
64. da Costa M.C., de Castro I., Neto A.L.C., Ferreira A.T., Burdmann E.A., Yu L. Cyclosporin A tubular effects contribute to nephrotoxicity: role for Ca2+ and Mg2+ ions. Nephrol Dial Transplant 2003, 18:2262-2268.
65. Fandrey J., Rob P.M., Jelkmann W. Theophylline and magnesium inhibit the contraction elicited with ciclosporin and angiotensin II in mesangial cell cultures. Nephron 1991, 57:94-98.
66. Collins G.M., Barry J.M., Maxwell J.G., Sampson D., Vander Werf B.A. The value of magnesium in flush solutions for human cadaveric kidney preservation. J Urol 1984, 131:220-222.
67. Lytton B., Vaisbort V.R., Glazier W.B., Chaudry I.H., Baue A.E. Improved renal function using adenosine triphosphate-magnesium chloride in preservation of canine kidneys subjected to warm ischemia. Transplantation 1981, 31:187-189.
68. Alves S.C., Tomasi C.D., Constantino L., et al. Hypomagnesemia as a risk factor for the non-recovery of the renal function in critically ill patients with acute kidney injury. Nephrol Dial Transplant 2013, 28:910-916.
69. Weglicki W.B., Phillips T.M., Mak I.T., et al. Cytokines, neuropeptides, and reperfusion injury during magnesium deficiency. Ann N Y Acad Sci 1994, 723:246-257.
70. Weglicki W.B., Chmielinska J.J., Kramer J.H., Mak I.T. Cardiovascular and intestinal responses to oxidative and nitrosative stress during prolonged magnesium deficiency. Am J Med Sci 2011, 342:125-128.
71. Altura B.M., Shah N.C., Shah G., et al. Short-term magnesium deficiency upregulates ceramide synthase in cardiovascular tissues and cells: cross-talk among cytokines, Mg2+, NF-kappaB, and de novo ceramide. Am J Physiol Heart Circ Physiol 2012, 302:H319-H332.
72. Touyz R.M. Role of magnesium in the pathogenesis of hypertension. Mol Aspects Med 2003, 24:107-136.
73. de Araujo M., Andrade L., Coimbra T.M., Rodrigues A.C., Seguro A.C. Magnesium supplementation combined with N-acetylcysteine protects against postischemic acute renal failure. J Am Soc Nephrol 2005, 16:3339-3349.
74. Kao W.H.L., Folsom A.R., Nieto F.J., Mo J.-P., Watson R.L., Brancati F.L. Serum and dietary magnesium and the risk for type 2 diabetes mellitus: the atherosclerosis risk in communities study. Arch Intern Med 1999, 159:2151-2159.
75. Larsson S.C., Wolk A. Magnesium intake and risk of type 2 diabetes: a meta-analysis. J Intern Med 2007, 262:208-214.
76. Suarez A., Pulido N., Casla A., Casanova B., Arrieta F.J., Rovira A. Impaired tyrosine-kinase activity of muscle insulin receptors from hypomagnesaemic rats. Diabetologia 1995, 38:1262-1270.
77. Mooren F.C., Kruger K., Volker K., Golf S.W., Wadepuhl M., Kraus A. Oral magnesium supplementation reduces insulin resistance in non-diabetic subjects - a double-blind, placebo-controlled, randomized trial. Diabetes Obes Metab 2011, 13:281-284.
78. Van Laecke S., Van Biesen W., Verbeke F., De Bacquer D., Peeters P., Vanholder R. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. Am J Transplant 2009, 9:2140-2149.
79. Van Laecke S., Nagler E.V., Taes Y., Van Biesen W., Peeters P., Vanholder R. The effect of magnesium supplements on early post-transplantation glucose metabolism: a randomized controlled trial. Transpl Int 2014, 27:895-902.
80. Garg N., Weinberg J., Ghai S., et al. Lower magnesium level associated with new-onset diabetes and pre-diabetes after kidney transplantation. J Nephrol 2014, 27:339-344.
81. Santos L., Rodrigo E., Pinera C., et al. Elevated serum gamma-glutamyltransferase and hypomagnesemia are not related with new-onset diabetes after transplantation. Transplant Proc 2010, 42:2914-2916.
82. Osorio J.M., Bravo J., Perez A., Ferreyra C., Osuna A. Magnesemia in renal transplant recipients: relation with immunosuppression and posttransplant diabetes. Transplant Proc 2010, 42:2910-2913.
83. Augusto J.F., Subra J.F., Duveau A., et al. Relation between pretransplant magnesemia and the risk of new onset diabetes after transplantation within the first year of kidney transplantation. Transplantation 2014, 97:1155-1160.
84. Nguyen T., Steiner R.W. A trial of oral magnesium supplementation in renal transplant recipients receiving cyclosporine. Transplant Proc 1998, 30:4317-4319.
85. Gupta B.K., Glicklich D., Tellis V.A. Magnesium repletion therapy improved lipid metabolism in hypomagnesemic renal transplant recipients: a pilot study. Transplantation 1999, 67:1485-1487.
86. Van Laecke S., Marechal C., Verbeke F., et al. The relation between hypomagnesaemia and vascular stiffness in renal transplant recipients. Nephrol Dial Transplant 2011, 26:2362-2369.
87. Verbeke F., Maréchal C., Van Laecke S., et al. Aortic stiffness and central wave reflections predict outcome in renal transplant recipients. Hypertension 2011, 58:833-838.
88. Shechter M., Sharir M., Labrador M.J.P., Forrester J., Silver B., Bairey Merz C.N. Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation 2000, 102:2353-2358.
89. Salem S., Bruck H., Bahlmann F.H., et al. Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. Am J Nephrol 2012, 35:31-39.
90. Afsar B., Elsurer R. The relationship between magnesium and ambulatory blood pressure, augmentation index, pulse wave velocity, total peripheral resistance, and cardiac output in essential hypertensive patients. J Am Soc Hypertens 2014, 8:28-35.
91. Joannides R., Monteil C., de Ligny B.H., et al. Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine. Am J Transplant 2011, 11:2414-2422.
92. Zheng J., Mao X., Ling J., He Q., Quan J., Jiang H. Association between serum level of magnesium and postmenopausal osteoporosis: a meta-analysis. Biol Trace Elem Res 2014, 159:8-14.
93. Orchard T.S., Larson J.C., Alghothani N., et al. Magnesium intake, bone mineral density, and fractures: results from the Women's Health Initiative Observational Study. Am J Clin Nutr 2014, 99:926-933.
94. Castiglioni S., Cazzaniga A., Albisetti W., Maier J. Magnesium and osteoporosis: current state of knowledge and future research directions. Nutrients 2013, 5:3022-3033.
95. Jeon S.-H., Kim S.-J., Kim J.-S., Kang H.-S. Immunosuppressant FK506 decreases the intracellular magnesium in the human osteoblast cell by inhibiting the ERK1/2 pathway. Life Sci 2009, 84:23-27.
96. Abed E., Moreau R. Importance of melastatin-like transient receptor potential 7 and magnesium in the stimulation of osteoblast proliferation and migration by platelet-derived growth factor. Am J Physiol Cell Physiol 2009, 297:C360-C368.
97. Iyer S.P., Nikkel L.E., Nishiyama K.K., et al. Kidney transplantation with early corticosteroid withdrawal: paradoxical effects at the central and peripheral skeleton. J Am Soc Nephrol 2014, 25:1331-1341.
98. Rodríguez-Ortiz M.E., Canalejo A., Herencia C., et al. Magnesium modulates parathyroid hormone secretion and upregulates parathyroid receptor expression at moderately low calcium concentration. Nephrol Dial Transplant 2014, 29:282-289.
99. Ohya M., Negi S., Sakaguchi T., et al. Significance of serum magnesium as an independent correlative factor on the parathyroid hormone level in uremic patients. J Clin Endocrinol Metab 2014, 99:3873-3878.
100. Tam M., Gomez S., Gonzalez-Gross M., Marcos A. Possible roles of magnesium on the immune system. Eur J Clin Nutr 2003, 57:1193-1197.
101. Deason-Towne F., Perraud A.L., Schmitz C. Identification of Ser/Thr phosphorylation sites in the C2-domain of phospholipase C 2 (PLC2) using TRPM7-kinase. Cell Signal 2012, 24:2070-2075.
102. Li F.-Y., Chaigne-Delalande B., Kanellopoulou C., et al. Second messenger role for Mg2+ revealed by human T-cell immunodeficiency. Nature 2011, 475:471-476.
103. Chaigne-Delalande B., Li F.-Y., O'Connor G.M., et al. Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. Science 2013, 341:186-191.
104. Mazur A., Maier J.A.M., Rock E., Gueux E., Nowacki W., Rayssiguier Y. Magnesium and the inflammatory response: potential physiopathological implications. Arch Biochem Biophys 2007, 458:48-56.
105. Sugimoto J., Romani A.M., Valentin-Torres A.M., et al. Magnesium decreases inflammatory cytokine production: a novel innate immunomodulatory mechanism. J Immunol 2012, 188:6338-6346.
106. Cojocaru I.M., Cojocaru M., Tanasescu R., Iacob S.A., Iliescu I. Changes of magnesium serum levels in patients with acute ischemic stroke and acute infections. Rom J Intern Med 2009, 47:169-171.
107. Soliman H.M., Mercan D., Lobo S.S.M., Melot C., Vincent J.-L. Development of ionized hypomagnesemia is associated with higher mortality rates. Crit Care Med 2003, 31:1082-1087.
108. Salem M., Kasinski N., Munoz R., Chernow B. Progressive magnesium deficiency increases mortality from endotoxin challenge: protective effects of acute magnesium replacement therapy. Crit Care Med 1995, 23:108-118.
109. Chung H.S., Park C.S., Hong S.H., et al. Effects of magnesium pretreatment on the levels of T helper cytokines and on the severity of reperfusion syndrome in patients undergoing living donor liver transplantation. Magnes Res 2013, 26:46-55.
110. D'Elios M.M., Josien R., Manghetti M., et al. Predominant Th1 cell infiltration in acute rejection episodes of human kidney grafts. Kidney Int 1997, 51:1876-1884.
111. Hulin A., Lamrani L., Sabbagh F., et al. Magnesium-deficiency does not alter calcineurin inhibitors activity in mice. Transpl Immunol 2012, 26:55-61.
112. Touyz R.M., Pu Q., He G., et al. Effects of low dietary magnesium intake on development of hypertension in stroke-prone spontaneously hypertensive rats: role of reactive oxygen species. J Hypertens 2002, 20:2221-2232.
113. Hans C.P., Chaudhary D.P., Bansal D.D. Effect of magnesium supplementation on oxidative stress in alloxanic diabetic rats. Magnes Res 2003, 16:13-19.